Can you take Cemiplimab with Romidepsin?

romiDEPsin has a moderate potential interaction with Arrhythmia.

The use of romidepsin may cause changes in ECG. It is recommended to consider cardiovascular monitoring of ECG prior to starting therapy and periodically during treatment in patients with congenital long QT syndrome, history of significant cardiovascular disease, and in patients taking anti-arrhythmic medicines or medicinal products that lead to significant QT prolongation. Confirm that potassium and magnesium levels are within normal range before administration of romidepsin. Care and close monitoring is recommended.

Cemiplimab has a major potential interaction with Autoimmune Disorders.

Cemiplimab can cause immune-mediated adverse reactions, which may be severe or fatal. Immune-mediated adverse reactions can occur in any organ system or tissue, can affect more than 1 body system simultaneously, and can occur at any time after starting therapy. Care should be exercised when using cemiplimab in patients with preexisting immune system disorders (e.g., ulcerative colitis, Crohn's disease, lupus) or with conditions affecting the nervous system (e.g., myasthenia gravis, Guillain-Barre syndrome). It is recommended to monitor patients closely for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Liver enzymes, creatinine, and thyroid function should be evaluated at baseline and periodically during therapy. If immune-mediated adverse reactions are suspected, appropriate workup should be started to exclude alternative etiologies (including infection). Medical management should be started promptly, including specialty consultation as appropriate. Cemiplimab should be withheld or permanently discontinued depending on severity.

romiDEPsin has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Cases of fatal and serious infections, including pneumonia, sepsis, and viral reactivation, including Epstein Barr and hepatitis B viruses have been reported with the use of romidepsin. The risk of life threatening infections may be greater in patients with a history of prior treatment with monoclonal antibodies directed against lymphocyte antigens and in patients with disease involvement of the bone marrow. Monitor reactivation in patients with evidence of prior hepatitis B infection as recommended and consider antiviral prophylaxis as clinically indicated.

Cemiplimab has a moderate potential interaction with Bone Marrow Transplantation.

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. It is recommended to follow patients closely for evidence of transplant-related complications and intervene promptly. The benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody before or after an allogeneic HSCT should be considered.

romiDEPsin has a moderate potential interaction with Cardiovascular Conditions and Disorders.

The use of romidepsin may cause changes in ECG. It is recommended to consider cardiovascular monitoring of ECG prior to starting therapy and periodically during treatment in patients with congenital long QT syndrome, history of significant cardiovascular disease, and in patients taking anti-arrhythmic medicines or medicinal products that lead to significant QT prolongation. Confirm that potassium and magnesium levels are within normal range before administration of romidepsin. Care and close monitoring is recommended.

Cemiplimab has a moderate potential interaction with History, Radiation Therapy.

Cemiplimab can cause immune-mediated pneumonitis. In patients treated with other programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies, the incidence of pneumonitis was higher in patients with prior thoracic radiation. Care should be exercised when using cemiplimab in patients who have received thoracic radiation. Cemiplimab should be withheld or permanently discontinued depending on severity of pneumonitis.

romiDEPsin has a moderate potential interaction with Infection.

Cases of fatal and serious infections, including pneumonia, sepsis, and viral reactivation, including Epstein Barr and hepatitis B viruses have been reported with the use of romidepsin. The risk of life threatening infections may be greater in patients with a history of prior treatment with monoclonal antibodies directed against lymphocyte antigens and in patients with disease involvement of the bone marrow. Monitor reactivation in patients with evidence of prior hepatitis B infection as recommended and consider antiviral prophylaxis as clinically indicated.

Cemiplimab has a moderate potential interaction with Infectious Gastroenteritis.

Cemiplimab can cause immune-mediated colitis, with a primary component of diarrhea. CMV infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis treated with programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies; repeating infectious workup should be considered in these patients to exclude alternative etiologies. Cemiplimab should be withheld or permanently discontinued depending on severity of colitis.

Cemiplimab has a moderate potential interaction with Inflammatory Bowel Disease.

Cemiplimab can cause immune-mediated colitis, with a primary component of diarrhea. CMV infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis treated with programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies; repeating infectious workup should be considered in these patients to exclude alternative etiologies. Cemiplimab should be withheld or permanently discontinued depending on severity of colitis.

Cemiplimab has a moderate potential interaction with Liver Disease.

Cemiplimab can cause immune-mediated hepatitis. Liver enzymes should be evaluated at baseline and periodically during therapy. Cemiplimab should be withheld or permanently discontinued depending on severity of hepatitis. Additionally, this drug has not been studied in patients with severe liver dysfunction (total bilirubin greater than 3 times the upper limit of normal [3 x ULN]); mild to moderate liver dysfunction (total bilirubin greater than 1 to 3 x ULN) had no clinically significant effect on the exposure of cemiplimab. Caution should be exercised when using cemiplimab in patients with liver dysfunction.

romiDEPsin has a moderate potential interaction with Liver Disease.

Romidepsin population pharmacokinetic analysis indicated that mild hepatic impairment had no significant influence on romidepsin pharmacokinetics. A dose reduction and close monitoring is recommended in patients with moderate and severe hepatic impairment.

romiDEPsin has a moderate potential interaction with Lymphocytopenia.

The use of romidepsin may cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia. It is recommended to monitor blood counts regularly during treatment, and if necessary to modify the dose of romidepsin according to clinical practices.

romiDEPsin has a moderate potential interaction with Neutropenia.

The use of romidepsin may cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia. It is recommended to monitor blood counts regularly during treatment, and if necessary to modify the dose of romidepsin according to clinical practices.

Cemiplimab has a moderate potential interaction with Organ Transplant.

Solid organ transplant rejection and other transplant (including corneal graft) rejection have been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. This may be considered when using PD-1/PD-L1 blocking antibodies in patients who have received a solid organ or other transplant.

Cemiplimab has a moderate potential interaction with Renal Dysfunction.

Cemiplimab can cause immune-mediated nephritis with renal dysfunction. Creatinine should be evaluated at baseline and periodically during therapy. Cemiplimab should be withheld or permanently discontinued depending on severity of nephritis. Additionally, renal dysfunction (CrCl at least 21 mL/min [determined by Cockcroft-Gault]) had no clinically significant effect on the exposure of cemiplimab. Care should be exercised when using cemiplimab in patients with renal dysfunction.

romiDEPsin has a moderate potential interaction with Renal Dysfunction.

Romidepsin population pharmacokinetic analysis indicated that romidepsin pharmacokinetics were not affected by renal impairment. Care and close monitoring is recommended when prescribing this agent to patients with end-stage renal disease as the pharmacokinetics of romidepsin have not been studied in these patients.

romiDEPsin has a moderate potential interaction with Thrombocytopenia.

The use of romidepsin may cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia. It is recommended to monitor blood counts regularly during treatment, and if necessary to modify the dose of romidepsin according to clinical practices.